| Ida-FLAG plus imatinib mesylate-induced molecular remission in a patient with chemoresistant Ph1+ acute myeloid leukemia. | |
| | |
MedLine Citation:
|
PMID: 14962264 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Imatinib mesylate is a potent, selective inhibitor of the tyrosine kinase activity of bcr-abl,which is now established as the state-of-the-art treatment for chronic, accelerated or even blastic phase of Philadelphia-positive [Ph(1)(+)] chronic myelogenous leukemia. It is also active in Ph(1)(+) acute lymphoblastic leukemia, but its role in Ph(1)(+) acute myeloid leukemia (AML) is less well investigated. We report here a patient with chemoresistant Ph(1)(+) AML, who responded promptly to one cycle of Ida-FLAG second-line chemotherapy by achieving complete morphologic, immunophenotypic, and cytogenetic remission but not a molecular one. The addition of imatinib mesylate led to a molecular remission, which is sustained for 10 months so far. |
| | |
Authors:
|
Nora-Athina Viniou; Theodoros P Vassilakopoulos; Xanthi Giakoumi; Marina Mantzouranis; Gerassimos A Pangalis |
Related Documents
:
|
10400374 - Tailoring the treatment of acute myeloid leukemia. 18720364 - Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndr... 22326484 - Effect of asthma exacerbations on health care costs among asthmatic patients with moder... 12469194 - Determination of the in vivo effects of prednisone on bcl-2 family protein expression i... 22445874 - Adult congenital heart disease: new challenges. 16798924 - Digital panoramic radiography: a reliable method to diagnose carotid artery atheromas? |
Publication Detail:
|
Type: Case Reports; Journal Article |
Journal Detail:
|
Title: European journal of haematology Volume: 72 ISSN: 0902-4441 ISO Abbreviation: Eur. J. Haematol. Publication Date: 2004 Jan |
Date Detail:
|
Created Date: 2004-02-13 Completed Date: 2004-03-05 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8703985 Medline TA: Eur J Haematol Country: Denmark |
Other Details:
|
Languages: eng Pagination: 58-60 Citation Subset: IM |
Affiliation:
|
First Department of Internal Medicine, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece. jbnv@otenet.gr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antineoplastic Agents / therapeutic use Antineoplastic Combined Chemotherapy Protocols / administration & dosage, therapeutic use* Cytarabine / administration & dosage Female Filgrastim / administration & dosage Humans Idarubicin / administration & dosage Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy* Piperazines / therapeutic use* Pyrimidines / therapeutic use* Salvage Therapy Treatment Outcome Vidarabine / administration & dosage, analogs & derivatives* |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Ida-FLAG protocol; 0/Piperazines; 0/Pyrimidines; 121181-53-1/Filgrastim; 147-94-4/Cytarabine; 152459-95-5/imatinib; 5536-17-4/Vidarabine; 58957-92-9/Idarubicin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Thalidomide for the treatment of idiopathic myelofibrosis.
Next Document: Successful treatment of chemotherapy-refractory Sézary syndrome with alemtuzumab (Campath-1H).